Adiponectin Blood Test Explained: What It Measures and Why It Is Used

This page is for educational purposes only and is not medical advice; consult a licensed physician about laboratory testing and about any result that appears on a report. Nothing here interprets an individual value, and no reference ranges are offered as guidance.

What adiponectin is and where it comes from

Adiponectin is a protein hormone belonging to the family of adipokines — signalling molecules released by adipose (fat) tissue. A 2020 review of adiponectin's physiology described it as an adipocyte-derived protein with wide-ranging roles in inflammation and metabolic regulation across multiple organ systems, and reported that it acts through adiponectin receptors expressed in tissues including liver, muscle and vasculature (PMID 32059381). Unlike many hormones, adiponectin circulates at comparatively high concentrations, which is one reason it can be measured reliably in routine serum or plasma samples.

Adiponectin does not circulate as a single uniform molecule. It assembles into several multimeric forms: low-molecular-weight trimers, middle-molecular-weight hexamers, and high-molecular-weight (HMW) complexes. A study of maternal plasma characterised these multimeric fractions separately rather than relying on a single total value, illustrating that the distribution between forms can be measured independently of the overall concentration (PMID 19031276). Researchers have treated the HMW fraction as biologically distinct in several disease settings, which matters when comparing results across publications.

What the adiponectin blood test measures

Sample type

Adiponectin is typically quantified in serum or in plasma collected with EDTA or heparin, depending on the assay manufacturer's validated protocol. Laboratories generally report results in micrograms per millilitre or milligrams per litre. Because adiponectin is stable enough to survive standard handling, most protocols rely on conventional venous collection, centrifugation and freezing of aliquots until batch analysis — the approach used in cohort work such as the analysis of adiponectin multimers in maternal plasma (PMID 19031276).

Assay types

• Total adiponectin immunoassay. Enzyme-linked immunosorbent assays (ELISA) are the most common format, with radioimmunoassay and bead-based multiplex panels also used in research laboratories. These report a single combined concentration across all multimer forms.
• Multimer-resolving assays. Some kits use protease digestion or antibodies selective for the HMW complex so that fractions can be reported separately. A study of patients with cerebral infarction measured adiponectin multimer levels rather than total adiponectin alone when comparing stroke subtypes (PMID 35085298).
• Ratio reporting. Some publications report the HMW-to-total ratio as a derived index; the separate quantification of multimers described in maternal plasma work shows how such ratios are generated (PMID 19031276).

Why adiponectin measurement appears in clinical and research settings

Adiponectin is not a routine screening test in most health systems. It appears far more often as a research analyte or as part of a specialist biomarker panel. The published rationale is that adiponectin concentrations track with adipose tissue biology, insulin sensitivity and inflammatory signalling, which makes it a candidate marker in conditions where those processes are central; the 2020 physiology review set out that rationale across inflammatory and metabolic disease (PMID 32059381).

Specific research contexts in which investigators have measured adiponectin include:

• Obesity-related cancer biology. A review of obesity-related gastrointestinal carcinogenesis examined adiponectin signalling as a mechanistic link between excess adiposity and tumour development in the digestive tract (PMID 25007742), and a broader review of adiponectin in cancer surveyed its multifaceted roles across tumour types (PMID 24417946).
• Prostate disease. A 2019 review assessed the role of adiponectin in prostate cancer, including its evaluation as a circulating marker in that setting (PMID 30648824).
• Kidney disease. A review of adiponectin in chronic kidney disease summarised findings on how circulating adiponectin behaves in renal impairment and what it has been reported to predict (PMID 28197480).
• Liver disease. A paper asking whether adiponectin is a biomarker for chronic hepatitis C reviewed its measurement in that infection (PMID 26683021).
• Rheumatic disease. A review examined adiponectin's multifaceted roles in rheumatoid arthritis (PMID 26307192), and a meta-analysis pooled serum adipokine levels, adiponectin among them, in patients with systemic sclerosis compared with controls (PMID 27321124).
• Sleep-disordered breathing. An umbrella review of meta-analyses on diagnostic and monitoring biomarkers of obstructive sleep apnoea considered adiponectin among the candidate analytes evaluated in that literature (PMID 36614858).
• Eye disease. A 2023 review asked whether adiponectin behaves as a "friendly adipokine" in diabetic retinopathy and reviewed the measurement evidence in that population (PMID 37157861).
• Cerebrovascular disease. A 2022 study examined the relationship between adiponectin multimer levels and subtypes of cerebral infarction (PMID 35085298).
• Pregnancy physiology. Maternal plasma adiponectin multimers have been profiled to describe how the different forms behave during gestation (PMID 19031276).

The decision to request this test, and the reason behind it, rests with the treating clinician, who will weigh the question being asked against whether a validated, locally available assay exists.

What published studies associate with lower adiponectin

The direction that receives the most attention in the literature is the inverse relationship between adiposity and circulating adiponectin. The 2020 review of adiponectin physiology reported that the hormone exerts insulin-sensitising and anti-inflammatory effects and described how those actions are diminished in metabolically adverse states (PMID 32059381). Reviews of obesity-related gastrointestinal cancer have built on that framework, examining reduced adiponectin signalling as one proposed mechanism connecting obesity with tumour biology (PMID 25007742).

In oncology more broadly, a review of adiponectin in cancer surveyed studies in which circulating levels were compared between patients and controls and in which adiponectin receptor signalling was investigated experimentally (PMID 24417946). The prostate cancer review covered the same question in a single tumour type and discussed adiponectin's relevance to disease biology and to risk assessment research (PMID 30648824). In ophthalmology, the diabetic retinopathy review weighed evidence on whether adiponectin is protective, harmful, or context-dependent in retinal disease, concluding that the label "friendly adipokine" required qualification (PMID 37157861).

What published studies associate with higher adiponectin

Higher adiponectin is not treated in the literature as uniformly favourable. The review of adiponectin in chronic kidney disease summarised recent findings in renal populations, where the relationship between circulating adiponectin and outcomes has not mirrored the pattern seen in uncomplicated metabolic disease (PMID 28197480). In inflammatory joint disease, the rheumatoid arthritis review described adiponectin as having multiple and sometimes opposing roles, including pro-inflammatory actions within the joint, rather than a single protective function (PMID 26307192).

In connective tissue disease, a meta-analysis pooled serum adipokine measurements, including adiponectin, in patients with systemic sclerosis against control groups (PMID 27321124). In viral hepatitis, researchers reviewed whether adiponectin measurement added information in chronic hepatitis C beyond existing markers (PMID 26683021). In cerebrovascular disease, the study of adiponectin multimers compared values across cerebral infarction subtypes, an analysis that would not have been possible with total adiponectin alone (PMID 35085298). The general lesson across these papers is that the clinical meaning of a high value depends on the disease context in which it was measured (PMID 32059381).

Research contexts at a glance

Assay and interpretation caveats: what studies report

Several limitations recur across this literature and shape how any reported value should be read by the clinician who requested it.

1. Total versus multimer measurement. Papers that quantified multimers separately, such as the maternal plasma analysis (PMID 19031276) and the cerebral infarction subtype study (PMID 35085298), are not directly comparable with studies reporting total adiponectin only.
2. No single standardised method. Immunoassays from different manufacturers differ in antibody specificity and calibration, so absolute concentrations are not interchangeable between laboratories; this is one reason the umbrella review of obstructive sleep apnoea biomarkers emphasised heterogeneity across the meta-analyses it pooled (PMID 36614858).
3. Context dependence. The same numerical value may carry opposite implications in a metabolic cohort versus a renal or inflammatory cohort, as reflected in the contrast between the kidney disease review (PMID 28197480) and the rheumatoid arthritis review (PMID 26307192).
4. Association is not causation. Most of the human data are observational. The cancer review made clear that adiponectin's roles are multifaceted and that mechanistic and epidemiological findings do not always align (PMID 24417946).
5. Biomarker status remains unsettled. The hepatitis C paper framed adiponectin's diagnostic value as a question rather than an established use (PMID 26683021), and the diabetic retinopathy review reached a similarly qualified conclusion (PMID 37157861).

What the test does not do on its own

No publication in the set above established adiponectin as a stand-alone diagnostic test for any condition. The umbrella review of obstructive sleep apnoea biomarkers evaluated candidate analytes against polysomnography-based diagnosis rather than proposing replacement of it (PMID 36614858), and the prostate cancer review positioned adiponectin within a wider picture of disease biology rather than as a single decisive measurement (PMID 30648824). A result is therefore interpreted alongside clinical findings, imaging and other laboratory data by the ordering clinician, who is also the correct person to explain the reference interval printed by the performing laboratory.

References

• Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases (International Journal of Molecular Sciences, 2020)
• Role of Adiponectin in prostate cancer (International Braz J Urol, 2019)
• Adiponectin and chronic kidney disease; a review on recent findings (Journal of Nephropharmacology, 2015)
• Potential Diagnostic and Monitoring Biomarkers of Obstructive Sleep Apnea-Umbrella Review of Meta-Analyses (Journal of Clinical Medicine, 2022)
• Role of adiponectin in obesity related gastrointestinal carcinogenesis (Cytokine & Growth Factor Reviews, 2015)
• Adiponectin: A biomarker for chronic hepatitis C? (Cytokine, 2017)
• Multifaceted roles of adiponectin in rheumatoid arthritis (International Immunopharmacology, 2015)
• Multifaceted roles of adiponectin in cancer (Best Practice & Research Clinical Endocrinology & Metabolism, 2014)
• Adiponectin: A "Friendly adipokine" in Diabetic Retinopathy? (Seminars in Ophthalmology, 2023)
• Serum adipokines levels in patients with systemic sclerosis: A meta-analysis (Modern Rheumatology, 2017)
• Adiponectin multimers in maternal plasma (Journal of Maternal-Fetal & Neonatal Medicine, 2008)
• Relationship between adiponectin multimer levels and subtypes of cerebral infarction (PLoS One, 2022)